Variant
FLT3 ITD & TKD MUTATIONS
CI-VAR-00002045Explore in graph →CIViC 3118
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28644114
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia2 | ||||||||
| FLT3 ITD & TKD MUTATIONS | Midostaurin | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID8516A Phase III Randomized, Double-Blind study of chemotherapy + Midostaurin or Placebo in newly diagnosed patients < 60 Years of age with FLT3 mutated Acute Myeloid Leukemia (AML). Overall survival was s… (full text at CIViC) PMID 28644114 · Stone et al., 2017 · Open in CIViC | civic |
| FLT3 ITD & TKD MUTATIONS | Sorafenib | Predictive | D | Supports Resistance | 3 | submitted | EID8914Murine pro-B lymphocyte lines Ba/F3 cells with FLT3-ITD were exposed to sorafenib with increasing low doses (i.e., 1-5 nmol/L) of sorafenib for up to 3 months, and further exposed for an additional 3 … (full text at CIViC) PMID 24619500 · Zhang et al., 2014 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available